Takeda Pharmaceutical Company Limited
TKPHF
$34.39
-$1.61-4.47%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 940.31% | -109.30% | 227.09% | -533.93% | -74.81% |
| Total Depreciation and Amortization | -1.38% | -0.26% | 28.32% | -20.06% | -5.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -38.18% | 415.98% | -145.14% | 57.58% | 22.06% |
| Change in Net Operating Assets | -271.56% | 163.75% | -1,337.72% | -96.76% | 222.17% |
| Cash from Operations | -5.57% | 71.95% | 2.32% | -42.07% | 33.12% |
| Capital Expenditure | 0.64% | 18.04% | -3.61% | -8.29% | 11.18% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | 20,951.43% | 300.00% | -73.09% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 755.56% | -98.82% | 181.84% | 770.93% | -77.21% |
| Other Investing Activities | -2,081.83% | 60.78% | -222.07% | 125.27% | -124.98% |
| Cash from Investing | -356.85% | -42.02% | -77.96% | 82.96% | -49.90% |
| Total Debt Issued | -100.00% | 86.60% | 567.72% | -31.28% | -91.61% |
| Total Debt Repaid | 96.77% | -66.70% | 20.55% | 54.79% | 6.50% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -3.25% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1,522.96% | 94.08% | -1,474.33% | 93.30% | -1,441.03% |
| Other Financing Activities | 15.65% | -120.53% | 53.27% | 2.69% | -26.65% |
| Cash from Financing | -1,437.05% | 94.54% | 24.86% | 53.96% | -480.96% |
| Foreign Exchange rate Adjustments | 60.71% | 637.51% | 73.51% | -142.43% | 153.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -107.66% | 1,024.77% | 66.02% | 70.10% | -758.53% |